ACG Case Reports Journal
Cure8 research brief
Why This Matters
This case series points to risankizumab as a potential option for children with IBD who have failed multiple biologics, and it reports use of noninvasive monitoring like intestinal ultrasound.
Who Should Pay Attention
Pediatric patients with refractory IBD and their caregivers; pediatric and adult clinicians who treat IBD; researchers studying biologics or pediatric IBD; patients who have failed prior biologic therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This report summarizes outcomes in nine pediatric patients who had failed multiple prior biologics and were treated with risankizumab. Response assessment included symptoms, biomarkers, endoscopy, and imaging; five patients achieved clinical remission while four did not.
The authors used noninvasive monitoring (including intestinal ultrasound) and reported no adverse events in this small series. Practical note Because this is a small case series (abstract-level summary) rather than a randomized trial, it cannot establish how effective or safe risankizumab is compared with other therapies.
Larger controlled studies in children are needed before changing standard practice.
Keep In Mind
Structured-content depth: abstract — the supplied text is an abstract/summary of a small case series. Findings come from nine patients and should be interpreted cautiously; the report does not replace randomized trial evidence.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACG Case Reports Journal
AuthorsAli Alsarhan, Balaji Krishnamurthy, Eman Elyyan +2 more
InstitutionAl Jalila Foundation
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 29, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
Outcomes of risankizumab use in adults with Crohn's disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study.
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...